ArticleAnnals of pediatric cardiology
Serum procalcitonin as a predictor of intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Article in Annals of pediatric cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reappraising the role of procalcitonin in predicting intravenous immunoglobulin resistance in Kawasaki disease.Annals of pediatric cardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Procalcitonin (PCT) has emerged as a potential biomarker for predicting resistance to intravenous immunoglobulin (IVIG) treatment and coronary artery abnormalities in Kawasaki disease (KD). This study aimed to evaluate the clinical utility of serum PCT in the management of KD. Materials and Methods: A retrospective analysis was performed on 170 patients with KD treated at a single center. Serum PCT levels were measured along with clinical and laboratory data. Patients were categorized as responders or nonresponders to IVIG treatment based on the resolution of fever following treatment. Logistic regression and receiver operating characteristic curve analysis were used to assess the predictive value of serum PCT. Results: Serum PCT levels were significantly higher in nonresponders compared to responders (1.40 ng/mL versus 0.32 ng/mL, Conclusions: Serum PCT is a useful biomarker for predicting resistance to IVIG treatment in KD. However, its utility for predicting coronary artery lesions is limited. Further multicenter studies are needed to validate these findings and standardize methodologies for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.